

PRELIMINARY AMENDMENT
U.S. Appl. No. 09/125,814

H1

hydroxypropylmethyl cellulose, methyl cellulose, hydroxyethyl cellulose,
and sodium carboxymethyl cellulose and

(iii) one or more of a water-absorbing and water-insoluble base
material selected from the group consisting of crystalline cellulose, α -
cellulose, cross-linked sodium carboxy-methyl cellulose, cross-linked
starch, chitin and chitosan,

(2) the content of the water-absorbing and gel-forming base material is about
5-40 wt% based on the total of the water-absorbing and water-insoluble base material
and the water-absorbing and gel-forming base material, and

(3) the drug is unevenly dispersed more on or in the water-absorbing and
water-insoluble base material than on or in the water-absorbing and gel-forming base
material, and

wherein 70 wt % or more based on the drug is dispersed on or in the water-
absorbing and water-insoluble base material and on or in the water-absorbing and gel-
forming base material.

H2

48. (amended) A powdery composition for nasal administration wherein

(1) the composition contains

(i) a drug,

(ii) one or more of a water-absorbing and gel-forming base material
selected from the group consisting of hydroxypropyl cellulose,
hydroxypropylmethyl cellulose, methyl cellulose, hydroxyethyl cellulose,
and sodium carboxymethyl cellulose and

PRELIMINARY AMENDMENT
U.S. Appl. No. 09/125,814

H2
cont

(iii) one or more of a water-absorbing and water-insoluble base material selected from the group consisting of crystalline cellulose, α -cellulose, cross-linked sodium carboxy-methyl cellulose, cross-linked starch, chitin and chitosan,

(2) the content of the water-absorbing and gel-forming base material is about 5-40 wt% based on the total of the water-absorbing and water-insoluble base material and the water-absorbing and gel-forming base material, and

(3) the drug is unevenly dispersed more on or in the water-absorbing and water-insoluble base material than on or in the water-absorbing and gel-forming base material,

wherein 60 wt % or more based on the drug is dispersed on or in the water-absorbing and water-insoluble base material.

49. (amended) The powdery composition according to claim 48, wherein 70 wt % or more based on the drug is dispersed on or in the water-absorbing and water insoluble base material.

50. (amended) The powdery composition according to claim 48, wherein 80 wt % or more based on the drug is dispersed on or in the water-absorbing and water insoluble base material.

Please add the following new claims:

51. (new) A powdery composition for nasal administration described in Claim

H3
Sub I

PRELIMINARY AMENDMENT
U.S. Appl. No. 09/125,814

46, wherein the state in which the drug is unevenly dispersed more on or in the water-absorbing and water-insoluble base material than on or in the water-absorbing and gel-forming base material is obtainable by a method that the drug is vigorously mechanically mixed with the water-absorbing and water-insoluble base material, in which at least 90 wt % based on the particles have an average particle diameter in the range of 10-350 μm , subsequently, the water-absorbing and gel-forming base material, in which at least 90 wt % based on the particles have an average particle diameter in the range of 10-350 μm , is mechanically mixed with the resultant mixture.

52. (new) A powdery composition for nasal administration described in Claim 46, wherein the powdery composition is obtainable by a method that the drug is allowed to adhere to the water-absorbing and water-insoluble base material by freeze drying, then, the water-absorbing and water-insoluble base material with the adhered drug is pulverized and sieved so that at least 90 wt % based on the resultant particles have an average particle diameter in the range of 10-350 μm , subsequently, the water-absorbing and gel-forming base material, in which at least 90 wt % based on the particles have an average particle diameter in the range of 10-350 μm , is mechanically mixed with the resultant water-absorbing and water-insoluble base material.

53. (new) A powdery composition for nasal administration described in Claim 46, wherein the powdery composition is obtainable by a method that the drug and the water-absorbing and water-insoluble base material are dissolved or dispersed in an organic solvent, and subsequently the resultant solution or dispersion is evaporated

PRELIMINARY AMENDMENT
U.S. Appl. No. 09/125,814

*intended
H3
cont*

such that a powder is obtained, further the powder is pulverized and sieved such that at least 90 wt% based on the resultant particles have an average particle diameter in the range of 10-350 μm , and the water-absorbing and gel-forming base material, in which at least 90 wt% based on the particles have an average particle diameter in the range of 10-350 μm , is mechanically mixed with the resultant powder.

*Sub I
cont*

54. (new) A powdery composition for nasal administration described in Claim 46, wherein the state in which the drug is dispersed more on or in the water-absorbing and water-insoluble base material than on or in the water-absorbing and gel-forming base material is obtainable by making the average particle diameter of the water-absorbing and water-insoluble base material larger than that of the water-absorbing and gel-forming base material.

55. (new) A powdery composition for nasal administration described in claim 54, wherein the water-absorbing and water-insoluble base material has an average particle diameter of 10-350 μm in at least 90 wt % based on the particles, and the water-absorbing and gel-forming base material has an average particle diameter of 10-105 μm in at least 90 wt % based on the particles.

56. (new) A powdery composition for nasal administration described in claim 54, wherein the water-absorbing and water-insoluble base material has an average particle diameter of 10-250 μm in at least 90 wt % based on the particles, and the water-absorbing and gel-forming base material has an average particle diameter of 10-65 μm

PRELIMINARY AMENDMENT
U.S. Appl. No. 09/125,814

in at least 90 wt % based on the particles.

A3
cont

57. (new) A powdery composition for nasal administration described in any one of Claims 46-47 and 51-54, wherein the drug is selected from the group consisting of non-peptide/non-proteinaceous drugs and peptide/proteinaceous drugs having molecular weight of 30,000 or less.

Sub I
cont

58. (new) A powdery composition for nasal administration described in Claim 57, wherein the non-peptide/non-proteinaceous drug is one or more drugs selected from the group consisting of anti-inflammatory steroids, nonsteroidal anti-inflammatory drugs, analgesic anti-inflammatory agents, antitussive expectorants, antihistaminic agents, antiallergic drugs, antiemetic drugs, hypnotics, vitamin preparations, sex steroid hormones, antineoplastic drugs, antiarrhythmic drugs, antihypertensive drugs, antianxiety drugs, psychotropic drugs, antiulcer drugs, cardiotonics, analgesics, bronchodilators, treating agents for obesity, antithrombotic drugs, antidiabetic drugs, muscle relaxants and anti-rheumatics.

59. (new) A powdery composition for nasal administration described in Claim 57, wherein the peptide/proteinaceous drug is one or more drugs selected from the group consisting of luteinizing hormone-releasing hormones, growth hormone-releasing factors, somatostatin derivatives, vasopressins, oxytocins, hirudin derivatives, enkephalins, adrenocorticotrophic hormone derivatives, bradykinin derivatives, calcitonins, insulins, glucagon derivatives, growth hormones, growth

PRELIMINARY AMENDMENT
U.S. Appl. No. 09/125,814

113
cont

hormone-releasing hormones, luteinizing hormones, insulin-like growth factors, calcitonin gene-related peptides, atrial natriuretic polypeptide derivatives, interferons, erythropoietin, granulocyte colony forming-stimulating factor, macrophage forming-stimulating factor, parathyroid hormones, parathyroid hormone-releasing hormone, prolactin, thyroid-stimulating hormone-releasing hormone and angiotensins.

Sub 1
cont

60. (new) A powdery composition for nasal administration described in any one of Claims 46-47 and 51-56, wherein the drug is a peptide/proteinaceous drug having a molecular weight of 500-1500, and the amount of the water-absorbing and gel-forming base material is about 5-30 wt % based on the total of the water-absorbing and water-insoluble base material and the water-absorbing and gel-forming base material.

61. (new) A powdery composition for nasal administration described in Claim 60, wherein the peptide/proteinaceous drug is one or more drugs selected from the group consisting of vasopressins, luteinizing hormone-releasing hormones, growth hormone-releasing factors, somatostatin derivatives, oxytocins, hirudin derivatives, enkephalins, adrenocorticotrophic hormone derivatives and bradykinin derivatives.

62. (new) A powdery composition for nasal administration described in any one of Claims 46-47 and 51-56, wherein the drug is a peptide/proteinaceous drug having a molecular weight of 1500-30,000 and the amount of the water-absorbing and gel-forming base material is about 5-20 wt % based on the total of the water-absorbing and water-insoluble base material and the water-absorbing and gel-forming base material.

PRELIMINARY AMENDMENT
U.S. Appl. No. 09/125,814

173
amt

63. (new) A powdery composition for nasal administration described in Claim 62, wherein the peptide/proteinaceous drug is one or more drugs selected from the group consisting of calcitonins, insulins, glucagon derivatives, growth hormones, growth hormone-releasing hormones, luteinizing hormones, insulin-like growth factors, calcitonin gene-related peptides, atrial natriuretic polypeptide derivatives, interferons, erythropoietin, granulocyte colony-stimulating factor, macrophage-stimulating factor, parathyroid hormones, parathyroid hormone-releasing hormone, prolactin, thyroid-stimulating hormone-releasing hormone and angiotensins.

Sub I
Contd

64. (new) A powdery composition for nasal administration described in any one of Claims 46-47 to 51-56, wherein the water-absorbing and water-insoluble base material is crystalline cellulose.

65. (new) A powdery composition for nasal administration described in any one of Claims 46-47 and 51-56, wherein the water-absorbing and gel-forming base material is hydroxypropyl cellulose.

66. (new) A powdery composition for nasal administration described in Claim 65, wherein the hydroxypropyl cellulose has a viscosity of 150-4000 cps in 2% aqueous solution.

67. (new) A powdery composition for nasal administration described in Claim

PRELIMINARY AMENDMENT
U.S. Appl. No. 09/125,814

A3
amt

46, wherein the state in which the drug is unevenly dispersed more on or in the water-absorbing and water-insoluble base material than on or in the water-absorbing and gel-forming base material is achieved by mechanically mixing the drug with the water-absorbing and water-insoluble base material, subsequently, adding the water-absorbing and gel-forming base material to the resultant mixture, and mechanically mixing thereof.

68. (new) A powdery composition for nasal administration described in Claim 67, wherein the mechanically mixing the drug with the water-absorbing and water-insoluble base material drug is vigorously mechanically mixing. *in latex?*

69. (new) A powdery composition for nasal administration described in Claim 46, wherein the state in which the drug is unevenly dispersed more on or in the water-absorbing and water-insoluble base material than on or in the water-absorbing and gel-forming base material is achieved by dissolving or dispersing the drug and the water-absorbing and water-insoluble base material in an aqueous solution, freeze drying the resultant solution for obtaining the drug-adhered to the water-absorbing and water-insoluble base material, pulverizing and sieving the resultant drug-adhered to the water-absorbing and water-insoluble base material for obtaining a powder fraction, adding the water-absorbing and gel-forming base material to the powder fraction, and mechanically mixing thereof.

70. (new) A powdery composition for nasal administration described in Claim

PRELIMINARY AMENDMENT
U.S. Appl. No. 09/125,814

#13
mt

46, wherein the state in which the drug is unevenly dispersed more on or in the water-absorbing and water-insoluble base material than on or in the water-absorbing and gel-forming base material is achieved by dissolving or dispersing the drug and the water-absorbing and water-insoluble base material in an organic solvent, evaporating the resultant solution for obtaining the drug-adhered to the water-absorbing and water-insoluble base material, pulverizing and sieving the resultant drug-adhered to the water-absorbing and water-insoluble base material for obtaining a powder fraction, adding the water-absorbing and gel-forming base material to the powder fraction, and mechanically mixing thereof.

71. (new) A powdery composition for nasal administration described in Claim 67, wherein average particle diameters of the water-absorbing and water-insoluble base material and the water-absorbing and gel-forming base material is at least 90 wt % based on the particles in the range of 10-350 μ m.

72. (new) A powdery composition for nasal administration described in claim 68, wherein average particle diameters of the water-absorbing and water-insoluble base material and the water-absorbing and gel-forming base material is at least 90 wt % based on the particles in the range of 10-350 μ m.

73. (new) A powdery composition for nasal administration described in claim 69, wherein average particle diameters of the water-absorbing and water-insoluble base material and the water-absorbing and gel-forming base material is at least 90 wt %

PRELIMINARY AMENDMENT
U.S. Appln. No. 09/125,814

7 based on the particles in the range of 10-350 μm .

A3
mt
74. (new) A powdery composition for nasal administration described in claim 70, wherein average particle diameters of the water-absorbing and water-insoluble base material and the water-absorbing and gel-forming base material is at least 90 wt % based on the particles in the range of 10-350 μm .

Anteveler
75. (new) A powdery composition for nasal administration described in Claim 48, wherein the state in which the drug is unevenly dispersed more on or in the water-absorbing and water-insoluble base material than on or in the water-absorbing and gel-forming base material is obtainable by a method that the drug is vigorously mechanically mixed with the water-absorbing and water-insoluble base material, in which at least 90 wt % based on the particles have an average particle diameter in the range of 10-350 μm , subsequently, the water-absorbing and gel-forming base material, in which at least 90 wt % based on the particles have an average particle diameter in the range of 10-350 μm , is mechanically mixed with the resultant mixture.

76. (new) A powdery composition for nasal administration described in Claim 48, wherein the powdery composition is obtainable by a method that the drug is allowed to adhere to the water-absorbing and water-insoluble base material by freeze drying, then, the water-absorbing and water-insoluble base material with the adhered drug is pulverized and sieved so that at least 90 wt % based on the resultant particles have an average particle diameter in the range of 10-350 μm , subsequently, the water-

PRELIMINARY AMENDMENT
U.S. Appln. No. 09/125,814

absorbing and gel-forming base material, in which at least 90 wt % based on the particles have an average particle diameter in the range of 10-350 μm , is mechanically mixed with the resultant water-absorbing and water-insoluble base material.

A3
cont

77. (new) A powdery composition for nasal administration described in Claim 48, wherein the powdery composition is obtainable by a method that the drug and the water-absorbing and water-insoluble base material are dissolved or dispersed in an organic solvent, and subsequently the resultant solution or dispersion is evaporated such that a powder is obtained, further the powder is pulverized and sieved such that at least 90 wt% based on the resultant particles have an average particle diameter in the range of 10-350 μm , and the water-absorbing and gel-forming base material, in which at least 90 wt% based on the particles have an average particle diameter in the range of 10-350 μm , is mechanically mixed with the resultant powder.

78. (new) A powdery composition for nasal administration described in Claim 48, wherein the state in which the drug is dispersed more on or in the water-absorbing and water-insoluble base material than on or in the water-absorbing and gel-forming base material is obtainable by making the average particle diameter of the water-absorbing and water-insoluble base material larger than that of the water-absorbing and gel-forming base material.

79. (new) A powdery composition for nasal administration described in claim 78, wherein the water-absorbing and water-insoluble base material has an average particle

PRELIMINARY AMENDMENT
U.S. Appl. No. 09/125,814

diameter of 10-350 μm in at least 90 wt % based on the particles, and the water-absorbing and gel-forming base material has an average particle diameter of 10-105 μm in at least 90 wt % based on the particles.

80. (new) A powdery composition for nasal administration described in claim 78, wherein the water-absorbing and water-insoluble base material has an average particle diameter of 10-250 μm in at least 90 wt % based on the particles, and the water-absorbing and gel-forming base material has an average particle diameter of 10-65 μm in at least 90 wt % based on the particles.

81. (new) A powdery composition for nasal administration described in any one of Claims 48-50 and 75-80, wherein the drug is selected from the group consisting of non-peptide/non-proteinaceous drugs and peptide/proteinaceous drugs having molecular weight of 30,000 or less.

82. (new) A powdery composition for nasal administration described in Claim 81, wherein the non-peptide/non-proteinaceous drug is one or more drugs selected from the group consisting of anti-inflammatory steroids, nonsteroidal anti-inflammatory drugs, analgesic anti-inflammatory agents, antitussive expectorants, antihistaminic agents, antiallergic drugs, antiemetic drugs, hypnotics, vitamin preparations, sex steroid hormones, antineoplastic drugs, antiarrhythmic drugs, antihypertensive drugs, antianxiety drugs, psychotropic drugs, antiulcer drugs, cardiotonics, analgesics, bronchodilators, treating agents for obesity, antithrombotic

PRELIMINARY AMENDMENT
U.S. Appl. No. 09/125,814

drugs, antidiabetic drugs, muscle relaxants and anti-rheumatics.

83. (new) A powdery composition for nasal administration described in Claim 81, wherein the peptide/proteinaceous drug is one or more drugs selected from the group consisting of luteinizing hormone-releasing hormones, growth hormone-releasing factors, somatostatin derivatives, vasopressins, oxytocins, hirudin derivatives, enkephalins, adrenocorticotrophic hormone derivatives, bradykinin derivatives, calcitonins, insulins, glucagon derivatives, growth hormones, growth hormone-releasing hormones, luteinizing hormones, insulin-like growth factors, calcitonin gene-related peptides, atrial natriuretic polypeptide derivatives, interferons, erythropoietin, granulocyte colony forming stimulating factor, macrophage forming-stimulating factor, parathyroid hormones, parathyroid hormone-releasing hormone, prolactin, thyroid-stimulating hormone-releasing hormone and angiotensins.

84. (new) A powdery composition for nasal administration described in any one of Claims 48-50 and 75-80, wherein the drug is a peptide/proteinaceous drug having a molecular weight of 500-1500, and the amount of the water-absorbing and gel-forming base material is about 5-30 wt % based on the total of the water-absorbing and water-insoluble base material and the water-absorbing and gel-forming base material.

85. (new) A powdery composition for nasal administration described in Claim 84, wherein the peptide/proteinaceous drug is one or more drugs selected from the group consisting of vasopressins, luteinizing hormone-releasing hormones, growth

PRELIMINARY AMENDMENT
U.S. Appl. No. 09/125,814

hormone-releasing factors, somatostatin derivatives, oxytocins, hirudin derivatives, enkephalins, adrenocorticotrophic hormone derivatives and bradykinin derivatives.

86. (new) A powdery composition for nasal administration described in any one of Claims 48-50 and 75-80, wherein the drug is a peptide/proteinaceous drug having a molecular weight of 1500-30,000 and the amount of the water-absorbing and gel-forming base material is about 5-20 wt % based on the total of the water-absorbing and water-insoluble base material and the water-absorbing and gel-forming base material.

87. (new) A powdery composition for nasal administration described in Claim 86, wherein the peptide/proteinaceous drug is one or more drugs selected from the group consisting of calcitonins, insulins, glucagon derivatives, growth hormones, growth hormone-releasing hormones, luteinizing hormones, insulin-like growth factors, calcitonin gene-related peptides, atrial natriuretic polypeptide derivatives, interferons, erythropoietin, granulocyte colony-stimulating factor, macrophage-stimulating factor, parathyroid hormones, parathyroid hormone-releasing hormone, prolactin, thyroid-stimulating hormone-releasing hormone and angiotensins.

88. (new) A powdery composition for nasal administration described in any one of Claims 48-50 and 75-80, wherein the water-absorbing and water-insoluble base material is crystalline cellulose.

89. (new) A powdery composition for nasal administration described in any one

PRELIMINARY AMENDMENT
U.S. Appl. No. 09/125,814

of Claims 48-50 and 75-80, wherein the water-absorbing and gel-forming base material is hydroxypropyl cellulose.

90. (new) A powdery composition for nasal administration described in Claim 89, wherein the hydroxypropyl cellulose has a viscosity of 150-4000 cps in 2% aqueous solution.

91. (new) A powdery composition for nasal administration described in Claim 48, wherein the state in which the drug is unevenly dispersed more on or in the water-absorbing and water-insoluble base material than on or in the water-absorbing and gel-forming base material is achieved by mechanically mixing the drug with the water-absorbing and water-insoluble base material, subsequently, adding the water-absorbing and gel-forming base material to the resultant mixture, and mechanically mixing thereof.

92. (new) A powdery composition for nasal administration described in Claim 91, wherein the mechanically mixing the drug with the water-absorbing and water-insoluble base material drug is vigorously mechanically mixing.

93. (new) A powdery composition for nasal administration described in Claim 48, wherein the state in which the drug is unevenly dispersed more on or in the water-absorbing and water-insoluble base material than on or in the water-absorbing and gel-forming base material is achieved by dissolving or dispersing the drug and the

PRELIMINARY AMENDMENT
U.S. Appl. No. 09/125,814

#3
Cmt

water-absorbing and water-insoluble base material in an aqueous solution, freeze drying the resultant solution for obtaining the drug-adhered to the water-absorbing and water-insoluble base material, pulverizing and sieving the resultant drug-adhered to the water-absorbing and water-insoluble base material for obtaining a powder fraction, adding the water-absorbing and gel-forming base material to the powder fraction, and mechanically mixing thereof.

94. (new) A powdery composition for nasal administration described in Claim 48, wherein the state in which the drug is unevenly dispersed more on or in the water-absorbing and water-insoluble base material than on or in the water-absorbing and gel-forming base material is achieved by dissolving or dispersing the drug and the water-absorbing and water-insoluble base material in an organic solvent, evaporating the resultant solution for obtaining the drug-adhered to the water-absorbing and water-insoluble base material, pulverizing and sieving the resultant drug-adhered to the water-absorbing and water-insoluble base material for obtaining a powder fraction, adding the water-absorbing and gel-forming base material to the powder fraction, and mechanically mixing thereof.

95. (new) A powdery composition for nasal administration described in Claim 91, wherein average particle diameters of the water-absorbing and water-insoluble base material and the water-absorbing and gel-forming base material is at least 90 wt % based on the particles in the range of 10-350 μm .

PRELIMINARY AMENDMENT
U.S. Appln. No. 09/125,814

96. (new) A powdery composition for nasal administration described in claim 92, wherein average particle diameters of the water-absorbing and water-insoluble base material and the water-absorbing and gel-forming base material is at least 90 wt % based on the particles in the range of 10-350 μm .

97. (new) A powdery composition for nasal administration described in claim 93, wherein average particle diameters of the water-absorbing and water-insoluble base material and the water-absorbing and gel-forming base material is at least 90 wt % based on the particles in the range of 10-350 μm .

98. (new) A powdery composition for nasal administration described in claim 94, wherein average particle diameters of the water-absorbing and water-insoluble base material and the water-absorbing and gel-forming base material is at least 90 wt % based on the particles in the range of 10-350 μm .